Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502887 | 0.86 | CACNA1B (0.61) | NAMPTCACNA1BAPBA1ALDH1A1HTT | |
| SCHEMBL13753440 | 0.82 | NAMPT (0.49) | NAMPTSMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL13116021 | 0.80 | ALDH1A1 (0.60) | NAMPTCACNA1BAPBA1ALDH1A1HTT | |
| SCHEMBL17633861 | 0.80 | CACNA1B (0.54) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13210697 | 0.79 | CACNA1B (0.85) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4169088 | 0.78 | SMN1; SMN2 (0.61) | NAMPTALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL10356571 | 0.78 | ALDH1A1 (0.69) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10357148 | 0.78 | ALDH1A1 (0.69) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10356572 | 0.78 | ALDH1A1 (0.69) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8101163 | 0.78 | CACNA1B (0.51) | CACNA1BAPBA1ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| US-6759433-B2 | FOR THERAPY OF PARKINSON'S DISEASE | RENOVIS, INC. | 2004-07-06 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| US-6509378-B2 | Parkinson's disease; ability to antagonize MPTP induced reduction in dopamine levels; amidation of the nitrobenzoyl halide with alkylamine | CENTAUR PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| US-6140369-A | PARTICULARLY, DOPAMINE DEPLETION-ASSOCIATED NEURODEGENERATIVE CONDITION OF THE CENTRAL NERVOUS SYSTEM; PARKINSON'S DISEASE; ALZHEIMER'S DISEASE; MITOCHONDRIAL DYSFUNCTION; ABNORMAL DOPAMINE DEPLETION IN SELECTED REGIONS OF THE BRAIN | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | disclosed |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | disclosed |
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-5756548-A | TREATMENT OF PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1997038684-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | NAMPT 1329/4885CACNA1B 1087/4885APBA1 29/4885 |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | NAMPT 1329/4885CACNA1B 1087/4885APBA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.